Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma

N. Syed, J. Joshi, P. Niphadkar, C. J. Po, M. Mangale, S. Chachad, S. Purandare, A. Sule, A. Lulla (Mumbai, India)

Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Session: Aspects of uncontrolled asthma
Session type: Thematic Poster Session
Number: 1990
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Syed, J. Joshi, P. Niphadkar, C. J. Po, M. Mangale, S. Chachad, S. Purandare, A. Sule, A. Lulla (Mumbai, India). Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma. Eur Respir J 2009; 34: Suppl. 53, 1990

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The combination salmeterol (S) + fluticasone propionate (F) in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010


Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Control of airway inflammation is maintained in asthma patients following a 60% reduction in ICS dose with fluticasone propionate/salmeterol (FSC) compared with higher dose fluticasone propionate (FP) alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004

Comparison of once-daily ciclesonide 160 μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 711s
Year: 2006

Comparison of fluticasone propionate plus theophylline with the salmeterol/fluticasone propionate combination in Japanese asthmatics
Source: Eur Respir J 2005; 26: Suppl. 49, 44s
Year: 2005

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice
Source: Eur Respir J 2006; 28: Suppl. 50, 713s
Year: 2006

Dynamics of lung function in children treated with salmeterol/ fluticasone propionate combination (SFC)
Source: Eur Respir J 2003; 22: Suppl. 45, 497s
Year: 2003

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 44s
Year: 2004

Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009